Acorn Capital Advisors Sells $5.2 Million Worth of Terns Pharmaceuticals Stock Amid 1,400% Gain

Acorn Capital Advisors sold 225,000 shares of Terns Pharmaceuticals for approximately $5.2 million, reducing its position to about 24% of its 13F AUM. Terns Pharmaceuticals' stock has soared 1,400% over the past year, significantly outperforming the S&P 500. The fund's recent sale may signal a repositioning among investors, despite still holding a significant stake in the company.